Department Clinical Oncology, St Imre Hospital, Tétényi út 12-15, 1116 Budapest, Hungary.
Pathol Oncol Res. 2012 Jul;18(3):669-74. doi: 10.1007/s12253-011-9493-5.
Malignant tumors are often accompanied by increased risk for procoagulant activity, thrombosis and embolism. As a marker indicating such disturbancies is D-dimer, a product of fibrinolysis. In this retrospective study almost 300 patients with malignant tumors were evaluated. During LMWH treatment (as thromboprophylaxis) the highest frequency of VTE with worst prognosis occurred in pancreatic cancer (partly due to the late discovery) followed by ovarian, colonic and breast cancers. Also, increased D-dimer level correlated with progression (stages) and high mortality rate. Furthermore, D-dimer showed very similar or better prognostic activity than the clinically widely used classic tumor markers and suggested to use it as an additional value..
恶性肿瘤常伴有促凝活性、血栓形成和栓塞的风险增加。D-二聚体作为纤维蛋白溶解的产物，是提示这种紊乱的标志物。在这项回顾性研究中，评估了近 300 名患有恶性肿瘤的患者。在低分子肝素治疗（作为血栓预防）期间，VTE 的最高频率和最差预后发生在胰腺癌（部分原因是发现较晚），其次是卵巢癌、结肠癌和乳腺癌。此外，D-二聚体水平的升高与进展（分期）和高死亡率相关。此外，D-二聚体显示出与临床广泛使用的经典肿瘤标志物非常相似或更好的预后活性，并建议将其用作附加价值。
